Latest Period
Q4 2025
Security Snapshot
Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) Institutional Ownership
CUSIP: 15117K103
13F Institutional Holders and Ownership History from Q1 2015 to Q1 2026
Institutions Reporting
34
Shares (Excl. Options)
10,548,060
Price
$4.84
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Ordinary Shares, nominal value EUR0.05 per share
- Symbol
- CLLS on Nasdaq
- Shares outstanding
- 95,490,450
- Price per share
- $3.36
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 10,548,060
- Total reported value
- $51,052,315
- % of total 13F portfolios
- 0%
- Share change
- +2,020,139
- Value change
- +$10,425,733
- Number of holders
- 34
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CLLS - Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share is tracked under CUSIP 15117K103.
- 34 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 34 to 5 between Q4 2025 and Q1 2026.
- Reported value moved from $51,052,315 to $393,028.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 34 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 15117K103?
CUSIP 15117K103 identifies CLLS - Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 15117K103:
Significant Owners of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ASTRAZENECA PLC | 44% | $66,440,000 | 44,000,000 | AstraZeneca PLC | 23 Jan 2025 | |||
| Bpifrance Participations SA | 11% | -15% | $33,176,247 | +$960,243 | 10,599,440 | +3% | Caisse des Depots | 03 Dec 2025 |
| Long Focus Capital Management, LLC | 4.6% | $6,972,112 | 4,617,293 | LONG FOCUS CAPITAL MANAGEMENT, LLC | 31 Dec 2024 |
As of 31 Dec 2025, 34 institutional investors reported holding 10,548,060 shares of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS). This represents 11% of the company’s total 95,490,450 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) together control 11% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| B Group, Inc. | 3.4% | 3,281,501 | 0% | 12% | $15,882,465 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.3% | 3,178,620 | 0% | $15,384,521 | |
| Long Focus Capital Management, LLC | 2.9% | 2,787,750 | -32% | 0.68% | $13,492,710 |
| BlackRock, Inc. | 0.4% | 384,299 | 0% | $1,860,007 | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 0.24% | 226,875 | 0% | 0% | $1,098,000 |
| MARSHALL WACE, LLP | 0.19% | 178,473 | +1610% | 0% | $863,809 |
| CITADEL ADVISORS LLC | 0.1% | 95,427 | -57% | 0% | $461,867 |
| MORGAN STANLEY | 0.09% | 87,176 | -0.57% | 0% | $421,932 |
| LPL Financial LLC | 0.09% | 84,792 | -0.42% | 0% | $410,393 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.05% | 52,423 | -2.7% | 0% | $253,727 |
| UBS Group AG | 0.05% | 50,100 | +71% | 0% | $242,484 |
| BNP PARIBAS FINANCIAL MARKETS | 0.04% | 41,300 | 0% | 0% | $199,892 |
| Point72 Asset Management, L.P. | 0.03% | 27,314 | 0% | $132,200 | |
| Delaney Dennis R | 0.03% | 24,000 | 0% | 0.06% | $116,160 |
| RHUMBLINE ADVISERS | 0.01% | 13,343 | +817% | 0% | $64,575 |
| Global Retirement Partners, LLC | 0.01% | 7,038 | 0% | $34,064 | |
| HARBOUR INVESTMENTS, INC. | 0% | 4,500 | 0% | 0% | $21,780 |
| NATIONAL BANK OF CANADA /FI/ | 0% | 3,600 | 0% | 0% | $17,208 |
| BANK OF AMERICA CORP /DE/ | 0% | 3,514 | +4464% | 0% | $17,008 |
| WELLS FARGO & COMPANY/MN | 0% | 3,150 | 0% | 0% | $15,246 |
| QUADRANT CAPITAL GROUP LLC | 0% | 2,761 | 0% | $13,364 | |
| CITIGROUP INC | 0% | 2,558 | +158% | 0% | $12,381 |
| Atlantic Union Bankshares Corp | 0% | 1,500 | 0% | 0% | $7,260 |
| Parallel Advisors, LLC | 0% | 1,479 | 0% | $7,158 | |
| Tower Research Capital LLC (TRC) | 0% | 1,133 | 0% | $5,484 |
Institutional Holders of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 125,008 | $393,028 | -$77,401 | $3.17 | 5 |
| 2025 Q4 | 10,548,060 | $51,052,315 | +$10,425,733 | $4.84 | 34 |
| 2025 Q3 | 8,311,195 | $23,687,285 | -$5,592,819 | $2.85 | 28 |
| 2025 Q2 | 11,757,728 | $17,853,958 | -$2,754,141 | $1.52 | 24 |
| 2025 Q1 | 13,602,212 | $16,864,343 | -$51,496 | $1.24 | 27 |
| 2024 Q4 | 12,759,251 | $22,964,294 | -$366,691 | $1.80 | 29 |
| 2024 Q3 | 9,766,379 | $20,863,531 | -$17,239 | $2.14 | 27 |
| 2024 Q2 | 9,772,625 | $18,275,141 | +$2,408,132 | $1.87 | 27 |
| 2024 Q1 | 9,854,602 | $26,115,627 | +$90,284 | $2.65 | 31 |
| 2023 Q4 | 9,816,725 | $30,235,236 | -$3,425,688 | $3.08 | 33 |
| 2023 Q3 | 11,480,546 | $18,138,183 | -$4,873,642 | $1.58 | 28 |
| 2023 Q2 | 14,008,673 | $27,590,926 | -$2,313,872 | $1.97 | 31 |
| 2023 Q1 | 15,157,594 | $29,256,650 | +$12,430,028 | $1.93 | 29 |
| 2022 Q4 | 8,733,333 | $18,344,069 | -$3,514,674 | $2.10 | 37 |
| 2022 Q3 | 10,299,547 | $23,616,856 | -$1,469,623 | $2.29 | 43 |
| 2022 Q2 | 10,831,048 | $30,655,602 | -$4,582,029 | $2.83 | 39 |
| 2022 Q1 | 12,267,940 | $55,746,674 | -$33,254,202 | $4.54 | 45 |
| 2021 Q4 | 15,187,964 | $123,726,723 | -$17,963,859 | $8.12 | 55 |
| 2021 Q3 | 15,388,771 | $194,068,172 | -$11,531,807 | $12.61 | 65 |
| 2021 Q2 | 16,213,399 | $250,623,262 | +$15,081,703 | $15.47 | 71 |
| 2021 Q1 | 15,242,452 | $308,003,839 | -$24,336,115 | $20.21 | 78 |
| 2020 Q4 | 16,303,634 | $441,619,228 | +$62,320,026 | $27.06 | 83 |
| 2020 Q3 | 14,221,535 | $263,393,288 | +$6,612,668 | $18.50 | 70 |
| 2020 Q2 | 13,884,259 | $246,854,298 | -$7,256,587 | $17.80 | 77 |
| 2020 Q1 | 14,368,296 | $132,185,088 | +$10,383,968 | $9.20 | 60 |
| 2019 Q4 | 13,222,126 | $226,376,965 | +$2,249,267 | $17.12 | 56 |
| 2019 Q3 | 13,148,118 | $136,738,200 | -$8,890,725 | $10.40 | 60 |
| 2019 Q2 | 13,435,563 | $209,551,644 | +$8,545,734 | $15.60 | 66 |
| 2019 Q1 | 12,740,024 | $233,652,737 | +$24,305,612 | $18.34 | 61 |
| 2018 Q4 | 11,487,097 | $191,259,158 | -$7,897,776 | $16.65 | 62 |
| 2018 Q3 | 11,517,705 | $325,035,828 | +$5,780,905 | $28.22 | 78 |
| 2018 Q2 | 11,275,435 | $319,022,621 | +$114,519,929 | $28.29 | 82 |
| 2018 Q1 | 7,051,580 | $222,126,151 | -$5,958,926 | $31.51 | 67 |
| 2017 Q4 | 7,308,253 | $213,043,133 | +$42,490,371 | $29.15 | 55 |
| 2017 Q3 | 5,872,301 | $167,046,670 | +$17,699,694 | $28.45 | 41 |
| 2017 Q2 | 5,258,779 | $135,752,000 | -$10,905,829 | $25.82 | 39 |
| 2017 Q1 | 5,703,192 | $136,879,000 | +$1,857,397 | $24.00 | 39 |
| 2016 Q4 | 5,670,274 | $96,110,000 | -$23,068,115 | $16.95 | 36 |
| 2016 Q3 | 6,638,753 | $159,861,000 | -$772,505 | $24.08 | 38 |
| 2016 Q2 | 6,932,847 | $184,344,000 | +$12,602,577 | $26.59 | 38 |
| 2016 Q1 | 6,465,692 | $177,790,378 | -$18,348,502 | $27.50 | 43 |
| 2015 Q4 | 7,051,276 | $218,793,000 | +$7,781,538 | $31.03 | 47 |
| 2015 Q3 | 6,877,612 | $181,305,000 | +$7,208,463 | $26.36 | 43 |
| 2015 Q2 | 6,601,328 | $238,170,032 | +$18,429,242 | $36.08 | 40 |
| 2015 Q1 | 6,124,463 | $211,832,000 | +$211,832,000 | $34.59 | 44 |